Quantcast

Latest Quest PharmaTech Inc. Stories

2011-07-21 10:59:00

TSX Venture: QPT EDMONTON, July 21, 2011 /PRNewswire/ - Quest PharmaTech Inc. (TSXV: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has received notice of allowance for U.S. Patent Application 10/831,886 entitled: "Combination Therapy for Treating Disease" (the "Patent"). The Patent covers the use of monoclonal antibodies capable of targeting tumor antigens CA 125, MUC1, CA 19.9,...

2011-06-07 10:20:00

TSX Venture: QPT EDMONTON, AB, June 7, 2011 /PRNewswire/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, announced today that it conducted its first clinical Investigators Meeting for Oregovomab in Rome, Italy. Oregovomab is an immunotherapeutic agent designed to trigger a specific immune response against CA125 expressing cancer, most notably ovarian. A seven center...

2011-04-14 08:30:00

TSX Venture: QPT EDMONTON, April 14 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced a clinical development arrangement with U.S. based Hemispherx Biopharma Inc. to evaluate the clinical utility of combining Quest's antibody immunotherapy technology with Hemispherx's immune activator in a thirty patient clinical trial. Under the...

2010-07-09 13:58:00

TSX Venture: QPT EDMONTON, July 9 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the formation of an international clinical advisory panel (the "Panel"). This Panel of international experts with special expertise in ovarian cancer has been charted to guide the Company through the conduct and analysis of its clinical trials program with...

2010-05-11 08:30:00

TSX Venture: QPT EDMONTON, May 11 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052...

2010-04-06 08:30:00

TSX Venture: QPT EDMONTON, April 6 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has completed a critical review of the development status for its recently acquired therapeutic antibody platform, conducted in association with external consultants and leading international experts in cancer therapeutics and immunology. Advances in the...

2009-09-30 11:38:00

TSX Venture: QPT EDMONTON, Sept. 30 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced that it has acquired a pipeline of late-stage immunotherapy product candidates from Paladin Labs Inc. (TSX:PLB) ("Paladin"). The pipeline of product candidates consists of five monoclonal antibodies targeting certain tumor antigens that are presented in a...

2009-03-18 06:00:00

TSX Venture: QPT EDMONTON, March 18 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced that it has formed a strategic alliance with IntelligentNano Inc. and, as a result of the alliance, the two groups have created a water soluble nano-formulation of Quest's SL052 technology, which has the potential to address a wider...

2009-03-04 11:36:00

TSX Venture: QPT EDMONTON, March 4 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company") a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced results from a study designed to investigate the effectiveness of its proprietary SL052 for photodynamic therapy (PDT) used in combination with immunotherapeutic agents in solid tumor animal models. The study, conducted by Dr. Mladen...

2009-02-02 06:00:00

TSX Venture: QPT EDMONTON, Feb. 2 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ("Quest" or the "Company"), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, announces that it has entered into an agreement with Loewen, Ondaatje, McCutcheon Limited ("LOM") to provide financial advisory services in connection with various business development opportunities. "The current capital market conditions have...


Word of the Day
siliqua
  • A Roman unit of weight, 1⁄1728 of a pound.
  • A weight of four grains used in weighing gold and precious stones; a carat.
  • In anatomy, a formation suggesting a husk or pod.
  • The lowest unit in the Roman coinage, the twenty-fourth part of a solidus.
  • A coin of base silver of the Gothic and Lombard kings of Italy.
'Siliqua' comes from a Latin word meaning 'a pod.'
Related